---
title: Ex Vivo Cancer Drug Screening Platform (EVIDENT)
summary: Developed a high-content ex vivo solid tumour biosample processing and drug efficacy screening platform using 2D/3D cell culture models, fluorescence and spatial imaging, and machine learning â€” to enable personalised cancer therapy selection for solid tumours including melanoma.
tags:
  - Oncology
  - Machine Learning
  - Drug Screening
  - Clinical Research
  - UK
date: 2021-10-01

# Optional external URL for project (replaces project detail page).
external_link: ''

image:
  caption: EVIDENT Project â€” University of Sheffield
  focal_point: Smart

links:
  - icon: university
    icon_pack: fas
    name: University of Sheffield
    url: https://www.sheffield.ac.uk
  - icon: book
    icon_pack: fas
    name: Publication
    url: https://www.tandfonline.com/doi/full/10.1080/1744666X.2024.2336583
---

## Overview

The **EVIDENT** (Ex Vivo Determined Cancer Therapy) project, funded by the Commonwealth PhD Scholarship (Â£158,685) and a UKRI Knowledge Exchange Fund grant (Â£10,890.67), developed a comprehensive ex vivo drug efficacy screening platform for solid cancers â€” with a focus on melanoma. The platform integrates biosample processing, 2D and 3D cell culture, high-content imaging, and machine learning to predict individual patient responses to targeted and immune therapies.

## Key Activities

- **Platform Development** â€” Developed end-to-end SOPs for solid tumour biosample collection, thermal chain maintenance, ex vivo processing, drug application, data recording, and long-term liquid nitrogen storage; included mock runs and QC protocols for stored samples and lab results
- **2D & 3D Cell Culture Models** â€” Established and optimised both conventional monolayer and patient-derived organoid/3D culture systems for drug efficacy assessment under physiologically relevant conditions
- **High-Content Imaging & Spatial Analysis** â€” Applied fluorescence microscopy and spatial imaging to quantify cell viability, morphology, and drug response across multiple assay conditions
- **Machine Learning for Image Analysis** â€” Trained a VGG19-based deep neural network for automated classification of biological imaging data, improving throughput and reproducibility of drug response quantification
- **Multivariate Statistical Modelling** â€” Conducted multivariate analysis on observational clinical and experimental data to identify predictors of drug response and patient outcomes
- **Knowledge Exchange** â€” Led translation activities with clinical partners under the UKRI Knowledge Exchange Fund, including a feasibility study for melanoma clinical deployment

## Outputs & Awards

- ğŸ† **BACR/AstraZeneca Student Award** (2023) â€” Travel grant to present at ESMO Congress, Barcelona
- ğŸ† **UKRI Knowledge Exchange Fund** (2023) â€” Â£10,890.67 for EVIDENT melanoma feasibility study
- ğŸ† **Commonwealth PhD Scholarship** â€” Â£158,685 (2021â€“2025)

## Selected Publications

- Rahman MM et al. (2024). [In-vitro assays for immuno-oncology drug efficacy assessment and screening for personalized cancer therapy: scopes and challenges.](https://www.tandfonline.com/doi/full/10.1080/1744666X.2024.2336583) *Expert Review of Clinical Immunology*
- Zhao A, ..., Rahman M, et al. (2024). SENP3-FIS1 axis promotes mitophagy. *Cell Death & Disease*
- [Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays](https://www.annalsofoncology.org/article/S0923-7534(23)02166-X/fulltext) â€” *Annals of Oncology* (Conference Abstract, ESMO 2023)

## Tools & Methods

`Python` Â· `R` Â· `VGG19 Deep Learning` Â· `High-Content Imaging` Â· `Spatial Transcriptomics` Â· `3D Cell Culture` Â· `Drug Screening Assays` Â· `Multivariate Statistics` Â· `SOPs & GLP`
